ecancermedicalscience

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

26 Nov 2014
Pan Pantziarka, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, Vikas P Sukhatme

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Related Articles

Nuradh Joseph, Vimukthini Peiris, Vodathi Bamunuarachchi, Prasad Abeysinghe, Nadarajah Jeyakumaran, Devinda Jayathilake, Kanthi Perera, Rohini Fernandopulle, Sanjeeva Gunasekera
Susan Msadabwe, Peng Yun Ng, Richard Sullivan, Kennedy Lishimpi, John Kachimba, Justor Banda, Jane Mumba, Abidan Chansa, Mutuna Chiwele, Kasonde Bowa, Kaseya Chiyenu, Linda Malulu-Chiwele, Julie Torode, Grant Lewison, Andrew Leather, Ajay Aggarwal, Kathleen Schmeler, Groesbeck Parham, Kabisa Mwala, Paul Kamfwa